Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (NASDAQ: PCRX) reported 12-month results from a 30-patient randomized pilot comparing iovera° cryoneurolysis to radiofrequency ablation (RFA) for facet-mediated chronic low back pain. The study found significantly lower pain scores with iovera° at Day 180 (3.1 vs 5.4, p=0.01) and Day 360 (3.0 vs 6.1, p=0.01), and better functional outcomes by Oswestry Disability Index at Day 360 (10.1 vs 20.6, p=0.002). Fewer iovera° patients required additional spine injections after 180 days (45.5% vs 75%). No treatment-related adverse events were reported during 12 months. The trial was unblinded and device length limited use to lower BMI patients; a new FDA-cleared SmartTip for deeper lumbar access was noted.
Pacira BioSciences (Nasdaq: PCRX) filed patent infringement lawsuits on November 26, 2025 against The WhiteOak Group and Qilu Pharmaceutical over EXPAREL® (bupivacaine liposome injectable suspension).
The filings seek injunctions and triggered a 30-month stay of final FDA approval for the ANDAs; EXPAREL is protected by 21 Orange Book patents with expirations in Jan 22, 2041 and Jul 2, 2044.
Pacira BioSciences (Nasdaq: PCRX) will participate in analyst-led fireside chats at two upcoming healthcare conferences: the Jefferies London Healthcare Conference on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET) and the 37th Annual Piper Sandler Healthcare Conference on Dec 2, 2025 at 1:30 PM ET.
Live audio of both events will be available on the company’s Events page at investor.pacira.com, and webcasts will be replayable for two weeks after each event.
Summary not available.
Pacira BioSciences (NASDAQ: PCRX) reported Q3 2025 revenues of $179.5M and updated full-year guidance on November 6, 2025. The company raised its full-year non-GAAP gross margin to 80–82% and reiterated other ranges while narrowing total revenue to $725M–$735M. Q3 results included EXPAREL net sales of $139.9M (volume +9%), adjusted EBITDA of $49.4M, GAAP net income of $5.4M (EPS $0.12), and non-GAAP net income of $31.8M (EPS $0.72 basic). Pacira repurchased 2.0M shares for $50.0M, ended the quarter with $246.3M cash, completed enrollment in Part A of its Phase 2 ASCEND PCRX-201 study, and in‑licensed AMT-143 under a deal with a $5.0M upfront payment.
Pacira BioSciences (Nasdaq: PCRX) announced it has concluded patient enrollment in Part A of the Phase 2 ASCEND study of PCRX-201 for osteoarthritis of the knee. Part A randomized ~45 patients 1:1:1 to two dose levels (1.4×1010 GC and 1.4×1011 GC) or saline, with steroid pretreatment for all cohorts. The study will enroll ~135 patients across Parts A and B; Part B will randomize ~90 patients using commercial-scale manufactured drug product. The primary endpoint is safety through Week 52; secondary endpoints include pain and function at Weeks 38 and 52 (NRS, WOMAC, KOOS). Pacira expects topline Part A results before the end of 2026 and will follow participants for five years.
Pacira BioSciences (NASDAQ: PCRX) entered an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a long-acting formulation of ropivacaine for postsurgical pain control.
The company said AMT-143 complements EXPAREL, advances Pacira's 5x30 pipeline strategy, and has a Phase 2 program expected to begin in 2026. Management indicated the asset could be meaningfully accretive to cash flow and earnings within the 5x30 timeframe.
Pacira (Nasdaq: PCRX) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a live conference call and webcast at 4:30 p.m. ET following the release.
Investors who wish to ask questions by phone must pre-register to receive dial-in details and a PIN. A live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible on the Pacira website for about two weeks after the call.
Pacira BioSciences (NASDAQ: PCRX) reported updated three-year results from its open-label Phase 1 trial of PCRX-201 for moderate-to-severe osteoarthritis of the knee. A single ultrasound-guided intra-articular injection at each of three dose levels was well tolerated and produced sustained, clinically meaningful reductions in pain and stiffness and improvements in function through 156 weeks in 72 patients across two cohorts.
Key findings include no serious treatment-related adverse events, lower treatment-related index joint effusion rates with corticosteroid pretreatment (42% vs 67%), pre-existing anti-AD5 neutralizing antibodies did not affect outcomes, and results support a Phase 2 ASCEND strategy using a 10-fold lower dose (1.4E11 GC) with corticosteroid pretreatment. Findings were presented at ACR Convergence 2025.
Pacira (Nasdaq: PCRX) said it received a Paragraph IV Certification Notice from Qilu Pharmaceutical (Hainan) Co., Ltd., which filed an ANDA with the FDA seeking approval of a generic version of EXPAR EL. Qilu alleges invalidity or noninfringement of 18 Orange Book-listed patents (U.S. Patent Nos. 11,033,495 through 12,370,142).
Pacira says the contested patents belong to two families expiring on January 22, 2041 and July 2, 2044. Pacira intends to enforce its IP and has 45 days to sue, which would trigger an automatic 30‑month FDA stay on Qilu’s ANDA approval under Hatch‑Waxman.